On 6 September 2024, Novo Nordisk announced its presentation of 21 abstracts and other data at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) held from 9 to 13 September 2024.
The data to be presented include results from the COMBINE clinical program of IcoSema (insulin icodec/semaglutide combination) in patients with type 2 diabetes, and the FLOW trial evaluating semaglutide 1mg on kidney outcomes in people with type 2 diabetes and chronic kidney disease (CKD).
The presentations also encompass results from studies on Awiqli® (once weekly basal insulin icodec) in type 2 diabetes; kidney, cardiovascular and all-cause mortality outcomes of Ozempic® (semaglutide 1mg) with or without baseline MRA use in type 2 diabetes and CKD; and analyses from studies on Wegovy® (semaglutide 2.4mg) and Saxenda® (liraglutide).
In August 2024, a representative from Novo Nordisk announced that the company was planning to submit regulatory approval applications for IcoSema in jurisdictions outside the US. Awiqli® (insulin icodec) has been approved in a number of jurisdictions including Europe (May 2024), Switzerland and Canada (June 2024), Japan (June 2024) and Australia (June 2024), and endorsed in China (June 2024).